Source: Dengyuemed | August 15, 2025 | Category: NCFB On August 13, 2025, the pharmaceutical sector rose by +1.73%, outperforming the CSI 300 Index by 0.94 percentage points, ranking 4th among Shenwan’s 31 sub-sectors. Leading…
At Dengyuemed, we closely follow breakthroughs in essential therapeutics and innovative drug developments. Dengyue is excited to share that China has just taken an important step forward in critical care support therapy. Recently, 25% High-Concentration…
Source: Dengyuemed | July 11, 2025 | Category: Rare Diseases On July 10, the General Office of the National Health Commission (NHC) of China officially released the 2025 Edition of Clinical Guidelines for 86 Rare…
On June 27, the corneal storage solution developed by the team at the Affiliated Eye Hospital of Shandong First Medical University and manufactured by Shandong Biodear Medical Devices Co., Ltd. (“Biodear”) officially received approval from…
On July 1, 2025, the initiation meeting for the Phase I clinical trial of IBR900 cellular injection—developed by ImmuneCell BioRay (Hangzhou) Co., Ltd.—for treating B-cell non-Hodgkin lymphoma was successfully held at Ruijin Hospital, Shanghai Jiao…
Dato DXd (datopotamab deruxtecan) has received U.S. FDA approval – a breakthrough milestone announced jointly by Daiichi Sankyo and AstraZeneca on June 23, 2025. The drug is indicated for the treatment of adults with locally…
— Reported by DengYueMed On June 24, 2024, Bio-Thera Solutions, Ltd. announced that its anti VEGF humanized monoclonal antibody BAT5906 has successfully met the primary endpoint in a pivotal Phase III clinical trial for the…
Molecular Glues: Unique Mechanism Of Action Wide Market Prospects Earlier this year, AbbVie announced a partnership with biotech company Neomorph for more than $1.6 billion to develop novel molecular glues protein degraders on multiple targets…
Novo Nordisk announced that its innovative growth hormone analogue Sogroya® (somapacitan) has been approved by the US Food and Drug Administration (FDA) for the treatment of growth hormone deficiency (GHD) in adults and children. As…
In a world still grappling with neglected tropical diseases, Impavido (generic name: miltefosine) remains one of the few oral treatments available for leishmaniasis, a parasitic infection that affects millions in impoverished and underserved regions. Despite…
Imdelltra™ (tarlatamab-dlle) represents a significant advancement in the treatment of extensive-stage small cell lung cancer (ES-SCLC), a particularly aggressive form of lung cancer. Developed by Amgen, this novel therapy received accelerated approval from the U.S.…
HYMPAVZI is the first and only anti-tissue factor pathway inhibitor (anti-TFPI) approved in the U.S. for the treatment of hemophilia A or B and the first hemophilia medicine approved in the U.S. to be administered…
